AI‑driven biotech insitro announced that its newly designed machine‑learning models for predicting in‑vivo pharmacokinetic behavior of small molecules are now available within Lilly’s TuneLab platform. The models aim to accelerate early‑stage drug discovery by forecasting absorption, distribution, metabolism, and excretion properties, reducing the need for costly animal studies. By integrating causal human biology insights with advanced algorithms, insitro hopes to streamline candidate selection and shorten development timelines.

The partnership with Eli Lilly underscores a growing trend of pharmaceutical firms embedding AI tools directly into their R&D pipelines. Industry analysts predict that such collaborations could cut preclinical costs by up to 30 % and improve success rates for first‑in‑human trials, potentially reshaping how new therapeutics reach the market.

This story was written by a language model from reporting by BioSpace. Check the original before quoting it.